Entrada Therapeutics (TRDA) Enterprise Value (2022 - 2025)
Entrada Therapeutics (TRDA) has 4 years of Enterprise Value data on record, last reported at -$91.1 million in Q4 2025.
- For Q4 2025, Enterprise Value rose 10.04% year-over-year to -$91.1 million; the TTM value through Dec 2025 reached -$91.1 million, up 10.04%, while the annual FY2025 figure was -$91.1 million, 10.04% up from the prior year.
- Enterprise Value reached -$91.1 million in Q4 2025 per TRDA's latest filing, up from -$93.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$45.2 million in Q4 2022 and bottomed at -$263.9 million in Q1 2022.
- Average Enterprise Value over 4 years is -$122.1 million, with a median of -$85.4 million recorded in 2023.
- Peak YoY movement for Enterprise Value: surged 75.93% in 2023, then crashed 132.31% in 2024.
- A 4-year view of Enterprise Value shows it stood at -$45.2 million in 2022, then plummeted by 49.7% to -$67.6 million in 2023, then plummeted by 49.72% to -$101.2 million in 2024, then grew by 10.04% to -$91.1 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$91.1 million in Q4 2025, -$93.3 million in Q3 2025, and -$72.5 million in Q2 2025.